How to Get Farxiga in Rhode Island

What Is Farxiga and Why Rhode Island Patients Seek It

Farxiga is the brand name for dapagliflozin, an oral sodium-glucose cotransporter-2 (SGLT2) inhibitor manufactured by AstraZeneca. It blocks glucose reabsorption in the proximal tubule of the kidney, lowering blood glucose, blood pressure, and intraglomerular pressure simultaneously. The FDA has approved it across three distinct indications: type 2 diabetes mellitus, heart failure (both reduced and preserved ejection fraction), and chronic kidney disease (CKD) in adults at risk of progression.

Rhode Island has a meaningful burden of all three conditions. The CDC estimates that 10.5% of U.S. adults have diabetes, and cardiovascular disease remains the leading cause of death in the state. [1] Demand for dapagliflozin has grown sharply since the DAPA-HF trial (N=4,744) demonstrated that dapagliflozin 10 mg reduced the composite of worsening heart failure or cardiovascular death by 26% versus placebo (hazard ratio 0.74; 95% CI 0.65-0.85; P<0.001) in patients with heart failure with reduced ejection fraction. [2] That single trial expanded the prescribing base well beyond endocrinologists to cardiologists, nephrologists, and primary care clinicians across the state.

The drug is available only by prescription in the United States. Rhode Island residents therefore need a licensed prescriber, adequate lab work, and either out-of-pocket funds or insurance coverage before they can fill the medication at a local or mail-order pharmacy.

Who Can Prescribe Farxiga in Rhode Island

Any Rhode Island-licensed prescriber with appropriate scope of practice may write a Farxiga prescription. Rhode Island grants nurse practitioners full practice authority under Rhode Island General Laws § 5-34-49, meaning NPs do not require physician supervision or a collaborative practice agreement to prescribe Schedule II-V controlled substances or non-controlled medications like dapagliflozin. [3] Physician assistants in Rhode Island practice under a supervision agreement but retain broad prescribing authority for non-controlled drugs.

In practice, Farxiga prescriptions in Rhode Island come from:

• Primary care physicians and internists managing type 2 diabetes or heart failure
• Cardiologists following patients post-hospitalization for heart failure
• Nephrologists managing CKD progression
• Endocrinologists optimizing glucose control
• Nurse practitioners in independent practice
• Physician assistants working within supervised settings
• Telehealth prescribers licensed in Rhode Island

Telehealth prescribing of dapagliflozin is fully legal in Rhode Island for both new and established patients. Rhode Island's telehealth parity law (R.I. Gen. Laws § 27-81) requires most insurers to cover telehealth visits at parity with in-person visits, which lowers the cost of obtaining a prescription remotely. [4] A prescriber must hold an active Rhode Island medical license regardless of where they physically sit during the visit.

Required Labs Before a Farxiga Prescription

Labs are straightforward. Getting this right upfront prevents a prescribing delay.

Before initiating dapagliflozin, the FDA label and American Diabetes Association (ADA) Standards of Care require assessment of kidney function because the drug's glucose-lowering efficacy diminishes at lower eGFR values. [5] The 2024 ADA Standards of Care state: "SGLT2 inhibitors should be initiated in patients with type 2 diabetes and eGFR ≥20 mL/min/1.73 m² for cardiorenal benefits, even when additional glucose lowering is not needed." [6]

Standard pre-prescription lab panel for Farxiga in Rhode Island:

1. Serum creatinine and eGFR (required; dose and indication eligibility depend on this value)
2. Complete metabolic panel (electrolytes, BUN, liver enzymes)
3. HbA1c (if diabetes is the indication; establishes baseline)
4. Urinalysis with microscopy (screens for urinary tract infection, glycosuria at baseline, and hematuria that could suggest renal pathology)
5. CBC (optional but common in CKD workup)

Most Rhode Island Quest Diagnostics and LabCorp locations can return results within 24-48 hours. Many telehealth platforms integrated into Rhode Island's health information exchange (CurrentCare) can access existing lab results with patient consent, potentially eliminating repeat draws if labs are current within 90 days.

Patients with eGFR <20 mL/min/1.73 m² should not initiate Farxiga for the diabetes indication. For heart failure and CKD indications, the FDA label permits initiation down to eGFR <25 mL/min/1.73 m² in some protocols, but this requires individualized prescriber judgment and closer monitoring. [7]

How to Get a Farxiga Prescription in Rhode Island: Step-by-Step

Getting a prescription is a four-step process and typically takes three to seven days from first contact to filled bottle.

Step 1: Schedule a visit (in-person or telehealth)

Book with a Rhode Island-licensed prescriber who has experience with SGLT2 inhibitors. Telehealth options are covered in the next section. If you already have a primary care provider in Rhode Island, request a medication review visit and mention your interest in Farxiga for the specific indication your condition matches.

Step 2: Complete pre-prescription labs

If your provider does not have recent labs on file, they will send an order to a local draw site. Quest Diagnostics has locations in Providence, Warwick, Cranston, and Woonsocket. LabCorp serves East Providence, Smithfield, and North Kingstown, among other locations. Results typically reach your provider within one to two business days.

Step 3: Attend the prescribing visit

Your provider reviews labs, confirms the indication (type 2 diabetes, heart failure, or CKD), discusses risks including genital mycotic infections, volume depletion, and the rare risk of diabetic ketoacidosis, and writes the prescription. The visit takes 20-40 minutes in-person or 15-30 minutes via video telehealth.

Step 4: Fill at a Rhode Island pharmacy or via mail order

Most major Rhode Island pharmacy chains (CVS, Walgreens, Rite Aid, independent pharmacies) stock Farxiga. The 30-day supply list price is approximately $550-$600 without insurance as of early 2025. AstraZeneca's Farxiga Savings Card can reduce out-of-pocket costs to as low as $10/month for commercially insured patients who meet eligibility criteria. [8]

Telehealth Options for Farxiga in Rhode Island

Telehealth is a practical and legal route for Rhode Island patients. Rhode Island's telehealth infrastructure is well-developed: the state's CurrentCare health information exchange allows providers to access shared patient records, which simplifies the remote evaluation process considerably.

Several categories of telehealth providers can prescribe Farxiga to Rhode Island residents:

• National telehealth platforms (e.g., Teladoc, MDLive, Amazon Clinic) that employ Rhode Island-licensed physicians and NPs
• Disease-specific telehealth services focused on cardiometabolic conditions, diabetes, and CKD management
• HealthRX telehealth (licensed in Rhode Island), which offers synchronous video visits for evaluation, lab order coordination, and ongoing monitoring for patients on dapagliflozin

An important practical note: Rhode Island's telehealth parity statute (§ 27-81) covers audio-only visits for established patients when video is unavailable. For a first-time Farxiga evaluation, most platforms require a video visit to meet prescribing standards for a new prescription of a chronic disease medication. The visit must document diagnosis, contraindications reviewed, labs confirmed, and patient education on side effects.

After the telehealth visit, the prescription is typically sent electronically to a pharmacy of your choice. Rhode Island participates in the national PDMP (Prescription Drug Monitoring Program), and dapagliflozin is non-controlled, so PDMP checks are not required but the prescription is still sent via eRx through standard NCPDP channels.

Rhode Island Insurance Coverage and Prior Authorization

Coverage varies significantly by payer and indication.

Rhode Island Medicaid (Medicaid Managed Care and fee-for-service): Farxiga is covered with prior authorization across all three FDA-approved indications. The PA typically requires documentation of:

• Confirmed diagnosis (ICD-10 codes E11.xx for T2D, I50.xx for heart failure, or N18.xx for CKD)
• Relevant lab values (HbA1c, eGFR)
• Trial and failure or contraindication to first-line agents where applicable (e.g., metformin for T2D)
• Prescriber attestation that the patient meets FDA-labeled criteria

Processing time for Rhode Island Medicaid PA requests averages 3-5 business days for standard review, or 72 hours for expedited review when clinical urgency is documented. Your prescriber's office or a telehealth platform's care coordinator typically handles PA submission.

Commercial insurance in Rhode Island: Blue Cross and Blue Shield of Rhode Island, Tufts Health Plan, and United Healthcare plans operating in Rhode Island generally place Farxiga on Tier 3 of their formularies, with PA requirements similar to Medicaid for the CKD and heart failure indications. Diabetes coverage PA criteria vary by plan year.

Medicare Part D: Dapagliflozin appears on most Part D formularies. The 2025 Medicare redesign caps out-of-pocket drug costs at $2,000 annually, which substantially reduces the burden for Medicare-enrolled Rhode Island patients on Farxiga.

Uninsured patients: AstraZeneca's patient assistance program (Farxiga 360 Support) provides free medication to qualifying patients with household income at or below 400% of the federal poverty level. [9] Applications are processed through the prescriber's office.

Transferring an Existing Farxiga Prescription to Rhode Island

Transferring a prescription is common when patients relocate or switch pharmacies.

Rhode Island pharmacy law permits the transfer of a non-controlled substance prescription between pharmacies in Rhode Island or from out-of-state pharmacies with valid licenses. To transfer your Farxiga prescription:

1. Contact your new Rhode Island pharmacy with the name and phone number of your current pharmacy.
2. The receiving pharmacist contacts the dispensing pharmacy to transfer the remaining refills electronically or by phone.
3. Original prescriptions for non-controlled drugs may be transferred once; after that, a new prescription from your prescriber is required.

If you are relocating to Rhode Island from another state and your prescriber is no longer licensed in Rhode Island, you will need a new evaluation by a Rhode Island-licensed provider. Most telehealth platforms can schedule this within 24-48 hours and, if recent labs are available, can often complete the prescription at the end of that single visit.

503A Compounding Pharmacies in Rhode Island

Farxiga is commercially available, so compounding is not a first-line option, but patient-specific circumstances sometimes make it appropriate.

Rhode Island-licensed 503A pharmacies are permitted to compound dapagliflozin for individual patients when a prescriber documents a specific clinical need, such as:

• Allergy to an inactive ingredient in the commercial tablet
• Required dose that differs from the commercially available 5 mg or 10 mg tablets
• Difficulty swallowing tablets, requiring a liquid formulation

503A compounding pharmacies in Rhode Island operate under state Board of Pharmacy oversight and must comply with USP chapter standards. They may not compound commercially available drugs in bulk without a valid patient-specific prescription. Any Rhode Island-licensed 503A pharmacy that ships compounded dapagliflozin must hold a non-resident pharmacy permit if shipping across state lines, and the receiving state's laws govern receipt. [10]

Patients considering compounded dapagliflozin should confirm with their prescriber that a clinical rationale exists, because most insurance plans (including Rhode Island Medicaid) will not cover compounded versions of commercially available drugs.

Monitoring While on Farxiga in Rhode Island

Starting Farxiga is not the end of the clinical process. Ongoing monitoring keeps patients safe and treatment effective.

The American College of Cardiology/American Heart Association (ACC/AHA) 2022 Heart Failure Guidelines recommend reassessment of eGFR and electrolytes 2-4 weeks after initiation of an SGLT2 inhibitor in heart failure patients. [11] For the CKD indication, the 2024 KDIGO CKD guidelines recommend eGFR monitoring at 2-4 weeks, then every 3-6 months depending on trajectory. [12]

Standard monitoring schedule for Farxiga:

| Timepoint | Tests | |---|---| | Baseline (before starting) | eGFR, CMP, HbA1c, urinalysis | | 4 weeks after initiation | eGFR, creatinine, blood pressure | | 3 months | HbA1c (if diabetes), eGFR, weight | | Every 6 months ongoing | eGFR, HbA1c, urinalysis, blood pressure |

Telehealth providers in Rhode Island can order follow-up labs through standing orders sent to local draw sites. CurrentCare results flow back to the ordering provider electronically, making remote monitoring fully functional without requiring in-person visits at every interval.

Patients should report symptoms of genital mycotic infection (itching, discharge, odor), urinary tract infection, or signs of volume depletion (dizziness, lightheadedness on standing) to their prescriber promptly. The DAPA-HF trial reported genital tract infections in 0.9% of the dapagliflozin group versus 0.1% in placebo over 18.2 months of follow-up. [2] Serious adverse events were rare but included diabetic ketoacidosis, which can occur even at blood glucose levels that appear normal.

Clinical Evidence Supporting Farxiga Prescribing

The evidence base for dapagliflozin is one of the strongest in the SGLT2 class.

In DAPA-HF (N=4,744, published NEJM 2019), dapagliflozin 10 mg daily reduced the primary composite endpoint of worsening heart failure or cardiovascular death by 26% (HR 0.74; 95% CI 0.65-0.85; P<0.001) in patients with HFrEF, regardless of diabetes status. [2] The benefit appeared within 28 days of initiation and was consistent across subgroups defined by age, sex, eGFR, and background therapy.

The DECLARE-TIMI 58 trial (N=17,160) evaluated dapagliflozin in adults with type 2 diabetes and established cardiovascular disease or multiple risk factors, showing a 27% relative risk reduction in hospitalization for heart failure (HR 0.73; 95% CI 0.61-0.88) compared with placebo. [13]

The DAPA-CKD trial (N=4,304) demonstrated a 39% reduction in the composite of sustained decline in eGFR of at least 50%, end-stage kidney disease, or death from renal or cardiovascular causes in patients with CKD and eGFR 25-75 mL/min/1.73 m² (HR 0.61; 95% CI 0.51-0.72; P<0.001). [14] This trial included patients with and without type 2 diabetes, establishing the drug's cardiorenal utility independent of glucose lowering.

Dr. John McMurray, lead investigator of DAPA-HF, stated in the NEJM publication: "The beneficial effects of dapagliflozin were consistent across all pre-specified subgroups... and were seen in patients with and without diabetes." [2] That finding was the clinical catalyst for broad adoption of SGLT2 inhibitors beyond the endocrinology specialty.

Costs and Savings Programs for Rhode Island Patients

The list price of Farxiga is approximately $550-$600 for a 30-day supply (10 mg tablets) at major Rhode Island pharmacies in early 2025. Out-of-pocket costs depend heavily on insurance tier placement and PA status.

Key savings options for Rhode Island residents:

• AstraZeneca Farxiga Savings Card: Commercially insured, eligible patients may pay as little as $10/month for up to 24 months. Income limits apply. [8]
• AstraZeneca Patient Assistance Program: Free medication for uninsured or underinsured patients meeting income criteria (generally <400% federal poverty level). [9]
• GoodRx and similar discount programs: GoodRx coupons for dapagliflozin at Rhode Island pharmacies bring the price down to approximately $400-$450/month, still significantly higher than co-pay card pricing.
• Generic dapagliflozin: As of early 2025, no FDA-approved generic dapagliflozin is available in the United States. The Farxiga patent is not expected to expire until 2025-2026; any generic entry would require FDA approval, manufacturing readiness, and supply chain build-out before reaching Rhode Island pharmacies.

Patients should ask their pharmacist to run both their insurance and a discount card to identify the lower price, as savings cards sometimes produce a lower cost than the insurance tier 3 co-pay.